Medicure (OTCMKTS:MCUJF – Get Free Report) and GRI Bio (NASDAQ:GRI – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Profitability
This table compares Medicure and GRI Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medicure | -9.62% | -10.12% | -7.13% |
| GRI Bio | N/A | -289.05% | -165.01% |
Insider and Institutional Ownership
34.0% of GRI Bio shares are owned by institutional investors. 12.9% of Medicure shares are owned by insiders. Comparatively, 0.1% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medicure | $16.07 million | 0.35 | -$680,000.00 | ($0.14) | -3.86 |
| GRI Bio | N/A | N/A | -$13.04 million | ($11.56) | -0.12 |
Medicure has higher revenue and earnings than GRI Bio. Medicure is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Medicure and GRI Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medicure | 0 | 0 | 0 | 0 | 0.00 |
| GRI Bio | 0 | 0 | 2 | 0 | 3.00 |
GRI Bio has a consensus price target of $195.50, suggesting a potential upside of 14,599.25%. Given GRI Bio’s stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than Medicure.
Risk & Volatility
Medicure has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.72, meaning that its stock price is 272% less volatile than the S&P 500.
Summary
Medicure beats GRI Bio on 7 of the 13 factors compared between the two stocks.
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
